Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | PPIA | P62937 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10592427 | 0.85 | CYP1A2 (0.53) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL1885996 | 0.82 | CYP1A2 (0.58) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL29838484 | 0.82 | GAA (0.67) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL526255 | 0.82 | GAA (0.67) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL6155867 | 0.82 | IDO1 (0.72) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL8419944 | 0.81 | GAA (0.61) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL3183964 | 0.81 | ALDH1A1 (0.63) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL18286554 | 0.81 | GAA (0.57) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL11849929 | 0.81 | GAA (0.61) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL11542953 | 0.80 | ALDH1A1 (0.67) | MAPTGAAALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115461969-A | Method for producing a laminated core, laminated core and electric machine | 蒂森克虏伯钢铁欧洲股份公司 | 2022-12-09 | — | — | CN | claimed |
| CN-113748586-A | Sheet material for producing electromagnetic components, in particular stator cores or rotor cores, and method for producing electromagnetic components | 蒂森克虏伯钢铁欧洲股份公司 | 2021-12-03 | — | — | CN | claimed |
| EP-3895279-A1 | SHEET METAL FOR PRODUCING AN ELECTROMAGNETIC COMPONENT, IN PARTICULAR A STATOR CORE OR A ROTOR CORE, AND METHOD FOR PRODUCING AN ELECTROMAGNETIC COMPONENT | ThyssenKrupp Steel Europe AG (DE) | 2021-10-20 | — | — | EP | claimed |
| WO-2020233841-A1 | SHEET METAL FOR PRODUCING AN ELECTROMAGNETIC COMPONENT, IN PARTICULAR A STATOR CORE OR A ROTOR CORE, AND METHOD FOR PRODUCING AN ELECTROMAGNETIC COMPONENT | THYSSENKRUPP STEEL EUROPE AG (DE) | 2020-11-26 | — | — | WO | claimed |
| CN-115461969-A | Method for producing a laminated core, laminated core and electric machine | 蒂森克虏伯钢铁欧洲股份公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-113748586-A | Sheet material for producing electromagnetic components, in particular stator cores or rotor cores, and method for producing electromagnetic components | 蒂森克虏伯钢铁欧洲股份公司 | 2021-12-03 | — | — | CN | disclosed |
| EP-2985281-B1 | ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CELGENE CORP (US) | 2017-12-27 | — | — | EP | disclosed |
| US-9796698-B2 | Isoindoline compounds and methods of their use | CELGENE CORPORATION (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170088538-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CELGENE CORPORATION | 2017-03-30 | — | — | US | disclosed |
| US-9550766-B2 | Isoindoline compounds and methods of their use | CELGENE CORPORATION (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160115161-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CELGENE CORPORATION | 2016-04-28 | — | — | US | disclosed |
| US-9227954-B2 | Isoindoline compounds and methods of their use | CELGENE CORPORATION (US) | 2016-01-05 | — | — | US | disclosed |
| US-20120252843-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CELGENE CORPORATION | 2012-10-04 | — | — | US | disclosed |
| US-8222249-B2 | Isoindoline compounds and methods of their use | CELGENE CORPORATION (US) | 2012-07-17 | — | — | US | disclosed |
| US-20120122865-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CELGENE CORPORATION | 2012-05-17 | — | — | US | disclosed |
| US-8129375-B2 | Isoindoline compounds and methods of their use | CELGENE CORPORATION (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129375-B2 | Isoindoline compounds and methods of their use | CELGENE CORPORATION (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100204227-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CELGENE CORPORATION | 2010-08-12 | — | — | US | disclosed |
| US-20100204227-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CELGENE CORPORATION | 2010-08-12 | — | — | US | disclosed |
| WO-2010053732-A1 | ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CELGENE CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088538-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CPT1A, CYP11B2, NPC1 | MAPT 565/4885GAA 560/4885ALDH1A1 674/4885 |
| US-20100204227-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CPT1A, CYP11B2, NPC1 | MAPT 565/4885GAA 560/4885ALDH1A1 674/4885 |
| US-20120252843-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CPT1A, CYP11B2, NPC1 | MAPT 565/4885GAA 560/4885ALDH1A1 674/4885 |
| US-20120122865-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CPT1A, CYP11B2, NPC1 | MAPT 565/4885GAA 560/4885ALDH1A1 674/4885 |
| US-20160115161-A1 | ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE | CPT1A, CYP11B2, NPC1 | MAPT 565/4885GAA 560/4885ALDH1A1 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.